Unknown

Dataset Information

0

Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.


ABSTRACT: HIV-mediated immune dysfunction may influence CD4(+) T cell recovery during suppressive antiretroviral therapy (ART). We analyzed cellular biomarkers of immunological inflammation, maturation, and senescence in HIV-infected subjects on early suppressive ART. We performed longitudinal analyses of peripheral immunological biomarkers of subjects on suppressive ART (n = 24) from early treatment (median 6.4 months, interquartile range [IQR] 4.8-13.9 months) to 1-2 years of follow-up (median 19.8 months, IQR 18.3-24.6 months). We performed multivariate regression to determine which biomarkers were associated with and/or predictive of CD4(+) T cell recovery. After adjusting for the pre-ART CD4(+) T cell count, age, proximal CD4(+) T cell count, and length of ART medication, the percentage of CD27(+)CD8(+) T cells remained significantly associated with the CD4(+) T cell recovery rate (? = 0.092 cells/ul/month, P = 0.028). In HIV-infected subjects starting suppressive ART, patients with the highest percentage of CD8(+) T cells expressing CD27 had the greatest rate of CD4(+) T cell recovery.

SUBMITTER: Seu L 

PROVIDER: S-EPMC3877182 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.

Seu Lillian L   Ortiz Gabriel M GM   Epling Lorrie L   Sinclair Elizabeth E   Swainson Louise A LA   Bajpai Urmila D UD   Huang Yong Y   Deeks Steven G SG   Hunt Peter W PW   Martin Jeffrey N JN   McCune Joseph M JM  

PloS one 20131231 12


HIV-mediated immune dysfunction may influence CD4(+) T cell recovery during suppressive antiretroviral therapy (ART). We analyzed cellular biomarkers of immunological inflammation, maturation, and senescence in HIV-infected subjects on early suppressive ART. We performed longitudinal analyses of peripheral immunological biomarkers of subjects on suppressive ART (n = 24) from early treatment (median 6.4 months, interquartile range [IQR] 4.8-13.9 months) to 1-2 years of follow-up (median 19.8 mont  ...[more]

Similar Datasets

| S-EPMC6695188 | biostudies-literature
| S-EPMC9259737 | biostudies-literature
| S-EPMC4638139 | biostudies-literature
| S-EPMC7889897 | biostudies-literature
| S-EPMC5640103 | biostudies-literature
| S-EPMC3480326 | biostudies-literature
2022-08-12 | PXD031628 | Pride
| S-EPMC10846540 | biostudies-literature
| S-EPMC3657555 | biostudies-literature
| S-EPMC8874604 | biostudies-literature